These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 18438840

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro.
    Thaher F, Plankenhorn S, Klein R.
    Int Immunopharmacol; 2011 Nov; 11(11):1724-31. PubMed ID: 21704732
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα.
    Shen Y, Li G, Gu C, Chen B, Chen A, Li H, Gao B, Liang C, Wu J, Yang T, Jin L, Su Y.
    PLoS One; 2017 Nov; 12(5):e0177891. PubMed ID: 28542350
    [Abstract] [Full Text] [Related]

  • 25. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioğlu E.
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Autoimmunity and anti-TNF-alpha agents.
    Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P.
    Ann N Y Acad Sci; 2005 Jun; 1051():559-69. PubMed ID: 16126996
    [Abstract] [Full Text] [Related]

  • 30. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [Abstract] [Full Text] [Related]

  • 33. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [Abstract] [Full Text] [Related]

  • 34. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS.
    J Infect Dis; 2006 Aug 15; 194(4):486-92. PubMed ID: 16845632
    [Abstract] [Full Text] [Related]

  • 35. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J, Hommes DW, Peppelenbosch MP.
    J Rheumatol Suppl; 2005 Mar 15; 74():26-30. PubMed ID: 15742461
    [Abstract] [Full Text] [Related]

  • 36. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE.
    Rev Gastroenterol Disord; 2004 Mar 15; 4(4):196-210. PubMed ID: 15580154
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May 15; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 40. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 May 15; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.